At a glance
A combined research record involving separate PT-141 and Melanotan II vials.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together separate PT-141 and Melanotan II vials. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of PT-141 + Melanotan II.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg + 10 mg · 2 source tables
PT-141 (Bremelanotide) — On-Demand Protocol (3 mL = ~3.33 mg/mL)
| Phase | Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Initial / Titration | 500–750 mcg | 15–22 units (0.15–0.22 mL) |
| Standard | 1000–1500 mcg | 30–45 units (0.30–0.45 mL) |
| Full / FDA-Approved | 1750 mcg (1.75 mg) | 52 units (0.52 mL) |
Route: Subcutaneous injection (abdomen or thigh). Frequency: On-demand, at least 45 minutes before anticipated sexual activity; no more than 1 dose per 24 hours and ≤8 doses per month[1][3]. Titration: Start at a lower dose (500–750 mcg) and increase as tolerated. Nausea is common with initial use and typically diminishes with subsequent doses[2][4].
Melanotan II — Daily Protocol (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 250 mcg | 7.5 units (0.075 mL)* |
| Week 2 | 500 mcg | 15 units (0.15 mL) |
| Weeks 3–4 | 750 mcg | 22 units (0.22 mL) |
| Weeks 5+ (Loading) | 1000 mcg | 30 units (0.30 mL) |
| Maintenance | 500–1000 mcg (2–3×/week) | 15–30 units (0.15–0.30 mL) |
Route: Subcutaneous injection (abdomen or thigh). Frequency: Once daily during loading phase; reduced frequency for maintenance[5][6]. *For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Titration: Begin at 250 mcg and increase by 250 mcg every 5–7 days as tolerated. Nausea and flushing are common initially and typically subside with continued use[6].
Additional schedule context & duration
Summary of both peptide regimens.
- PT-141: On-demand subcutaneous use for sexual function; typical dose 1.75 mg (1750 mcg) administered ≥45 min before activity[1].
- Melanotan II: Daily subcutaneous injections during loading phase (4–8 weeks), then 2–3× weekly maintenance for pigmentation and related effects[5].
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for both peptides.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).
Preparation
Reconstitution Steps (Both Peptides)
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct impact on the powder.
- Gently swirl or roll until fully dissolved (do not shake).
- Label with date, peptide name, and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use reconstituted solution within approximately 1 week for optimal stability[7].
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; PT-141 shows short-term room-temperature stability (~3 weeks) if needed[7].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 1 week for optimal potency.
- Avoid repeated freeze–thaw cycles; allow vials to reach room temperature before opening to reduce condensation.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[8][9].
- Clean the vial stopper with an alcohol swab; allow to dry completely.
- Clean the injection site (abdomen or thigh) with an alcohol swab for at least 30 seconds; allow to dry[8].
- Pinch a fold of skin; insert the needle at 45–90° depending on subcutaneous tissue depth[9][10].
- Aspiration is not required for subcutaneous injections; inject slowly and steadily[8].
- Release the skin fold, withdraw the needle, and apply gentle pressure if needed.
- Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy or irritation[9].
Materials & quantity planning
Source materials checklist · 10 mg + 10 mg
Plan based on an 8–16 week protocol. PT-141 assumes ~1 dose/week on-demand; Melanotan II assumes daily loading then maintenance.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Public health resource
FDA — Bremelanotide (Vyleesi) prescribing information: dosing, safety, and use limitations (opens in a new tab)www.accessdata.fda.gov
Back to overview ↑ - 02
Public health resource
NCBI Bookshelf (LiverTox) — Bremelanotide: mechanism, clinical use, and hepatic safety profile (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
PMC — Bremelanotide for treatment of female hypoactive sexual desire disorder: clinical trial review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Source document
Mayo Clinic — Bremelanotide (subcutaneous route): side effects, dosage, and precautions (opens in a new tab)www.mayoclinic.org
Back to overview ↑ - 05
Research publication
PubMed — Evaluation of Melanotan-II: pilot phase-I clinical study on safety and efficacy (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Source document
RxList — Melanotan-II: uses, side effects, dosing, and precautions overview (opens in a new tab)www.rxlist.com
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf (WHO) — Best practices for injections and related procedures: asepsis and technique (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Source document
Healthline — Subcutaneous injection: technique, sites, and step-by-step guidance (opens in a new tab)www.healthline.com
Back to overview ↑ - 10
Public health resource
CDC — Vaccine administration: subcutaneous injection angle and site selection (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
Research publication
PMC — Subcutaneous drug injection: pharmacologic considerations and clinical review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.